Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy

PLoS ONE

Volumn 3, Issue 5, 2008, Pages 1-12

  Cannon, Nathan A ^a   Donlin, Maureen J ^a   Fan, Xiaofeng ^a   Aurora, Rajeev ^a   Tavis, John E ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Saint Louis University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; VIRUS PROTEIN;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSENSUS SEQUENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MULTICENTER STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PHARMACOGENETICS; RELAPSE; SEQUENCE ANALYSIS; VIRAL GENETICS; VIRUS RESISTANCE; CLASSIFICATION; DRUG EFFECT; GENETICS; MIDDLE AGED; MOLECULAR EVOLUTION; MUTATION; RECURRENT DISEASE; TREATMENT FAILURE;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; CONSERVED SEQUENCE; EVOLUTION, MOLECULAR; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MIDDLE AGED; MUTATION; OPEN READING FRAMES; RECURRENCE; RIBAVIRIN; TREATMENT FAILURE; VIRAL PROTEINS;

EID: 48349131253     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002123     Document Type: Article

References (66)

1. (2004) Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 44: 20-29.
2. Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13: 2436-2441.
3. Armstrong GI, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
4. Kim WR, Brown RS Jr, Terrault NA, El-Serag H (2002) Burden of liver disease in the United States: summary of a workshop. Hepatology 36: 227-242.
5. Baker DE (2003) Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Reviews in Gastroenterological Disorders 2: 93-109.
6. Fried MW, Shiffman MI, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chrionic hepatitis C virus infection. New England Journal of Medicine 347: 975-982.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, et al. (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339: 1485-1492.
8. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, et al. (2006) Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131: 470-477.
9. Branch AD, Stump DD, Gutierrez JA, Eng F, Walewski JL (2005) The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. Semin Liver Dis 25: 105-117.
10. Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P (2002) Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 277: 17713-17721.
11. Walewski JL, Keller TR, Stump DD, Branch AD (2001) Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7: 710-721.
12. Bukh J, Miller R, Purcell R (1995) Genetic heterogeneity of hepatitis c virus: quasispecies and genotypes. Seminars in liver Disease 15: 41-63.
13. Robertson B, Myers G, Howard C, Brettin T, Bukh J, et al. (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Archives of Virology 143: 2493-2503.
14. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, et al. (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenctic analysis of the NS-5 region. Journal of General Virology 74: 2391-2399.
15. Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85: 3173-3188.
16. Simmonds P, Bukh J, Comber C, Deleage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
17. Gaudicri S, Rauch A, Park LP, Freitas E, Herrmann S, et al. (2006) Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol 80: 11094-11104.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
19. Strader DB, Wright T, Thomas DL, Seeff LB (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39: 1147-1171.
20. Gale MJ Jr, Korth MJ, Tang NM, Tan SL, Hopkins DA, et al. (1997) Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230: 217-227.
21. Dal PF, Tang KH, Gerotto M, Bortoletto G, Paulon E, et al. (2007) Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. J Infect Dis 196: 998-1005.
22. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, et al. (2006) Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 13: 582-590.
23. Veillon P, Payan C, Le Guillou-Guillemette H, Gaudy C, Lunel F (2007) Quasispecies evolution in NS5A region of hepatitis C virus genotype 1b during interferon or combined interferon-ribavirin therapy. World J Gastroenterol 13: 1195-1203.
24. Chayama K, Suzuki F, Tsubota A, Kobayashi M, Arase Y, et al. (2000) Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology 32: 1138-1144.
25. Gaudy C, Lambele M, Moreau A, Veillon P, Lunel F, et al. (2005) Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. J Clin Microbiol 43: 750-754.
26. Geriotto M, Dal PF, Pontisso P, Noventa F, Gatta A, et al. (2000) Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. Gastroenterology 119: 1649-1655.
27. Gupta R, Subramani M, Khaja MN, Madhavi C, Roy S, et al. (2006) Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in hepatitis C virus-infected patients in India. J Clin Microbiol 44: 709-715.
28. Hung CH, Lee CM, Lu SN, Lee JF, Wang JH, et al. (2003) Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 10: 87-94.
29. Puig-Basagoiti F, Saiz JC, Forns X, Ampurdanes S, Gimenez-Barcons M, et al. (2001) Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J Med Virol 65: 35-44.
30. Sarrazin C, Bruckner M, Herrmann E, Ruster B, Bruch Y, et al. (2001) Quasispecies heterogeneity ofthe carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. Virology 289: 150-163.
31. Yang SS, Lai MY, Chen DS, Chen GH, Kao JH (2003) Muations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin. Liver Int 23: 426-433.
32. Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. (2007) Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol 81: 8211-8224.
33. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
34. Macdonald A, Crowder K, Street A, McCormick C, Harris M (2004) The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J Gen Virol 85: 721-729.
35. van Doorn LJ, Capriles I, Maertens G, DeLeys R, Murray K, et al. (1995) Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol 69: 773-778.
36. Francois C, Duverlie G, Rebouillat D, Khorsi H, Castelain S, et al. (2000) Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J Virol 74: 5587-5596.
37. Taylor DR, Shi ST, Romano PR, Garber GN, Lai MMC (1999) Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285: 107-110.
38. Lorenz IC, Marcotrigiano J, Dentzer TG, Rice CM (2006) Structure of the catalytic domain of the hepatitis C virus NS2-3 protease. Nature 442: 831-835.
39. Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC (1999) Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7: 1353-1363.
40. Tellinghuisen TL, Marcotrigiano J, Rice CM (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435: 374-379.
41. O'Farrell D, Trowbridge R, Rowlands D, Jager J (2003) Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J Mol Biol 326: 1025-1035.
42. Poon AF, Kosakovsky Pond SL, Bennett P, Richman DD, Leigh Brown AJ, et al. (2007) Adaptation to human populations is revealed by within-host polymerphisms in HIV-1 and hepatitis C virus. PLoS Pathog 3: e45.
43. Abbate I, Lo IO, Di SR, Cappiello G, Girardi E, et al. (2004) HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 40: 831-836.
44. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, et al. (2005) Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 79: 3071-3083.
45. Forns X, Purcell RH, Bukh J (1999) Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 7: 402-410.
46. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, et al. (2006) Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis 193: 931-940.
47. von WM, Lee JH, Ruster B, Kronenberger B, Sarrazin C, et al. (2003) Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment. J Viral Hepat 10: 413-422.
48. Arataki K, Kumada H, Toyota K, Ohishi W, Takahashi S, et al. (2006) Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy. Intervirology 49: 352-361.
49. Chen S, Wang YM (2002) Genetic evolution of structural region of hepatitis C virus in primary infection. World J Gastroenterol 8: 686-693.
50. Odeberg J, Yun Z, Sonnerborg A, Weiland O, Lundeberg J (1998) Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. J Med Virol 56: 33-38.
51. Pawlotsky JM, Germanidi, G, Frainais PO, Bouvier M, Soulier A, et al. (1999) Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 73: 6490-6499.
52. Polyak SJ, McArdle S, Liu SL, Sullivan DG, Chung M, et al. (1998) Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 72: 4288-4296.
53. Kaukinen P, Sillanpaa M, Kotenko S, Lin R, Hiscott J, et al. (2006) Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/ chemokine gene expression. Virol J 3: 66.
54. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM (2007) Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 81: 8374-8383.
55. Brown RJ, Juttla VS, Tarr AW, Finnis R, Irving WL, et al. (2005) Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol 86: 1931-1942.
56. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, et al. (1995) Comparison of full-length sequences of interferon-sensitve and resistant hepatitis C virus 2b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 96: 224-230.
57. Vuillermoz I, Khattab E, Sablon E, Ottevaere I, Durantel D, et al. (2004) Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy. J Med Virol 74: 41-53.
58. Hamano, K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, et al. (2005) Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. J Gastroenterol Hepatol 20: 1401-1409.
59. Yao E, Tavis JE (2005) A general method for nested RT-PCR amplification and sequencing the complete HCV genotype I open reading frame. Virol J 2: 88.
60. Fan X, Xu Y, Di Bisceglie AM (2006) Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples. Biochem Biophys Res Commun 346: 1163-1172.
61. Walewski JL, Gutierrez JA, Branch-Elliman W, Stump DD, Keller TR, et al. (2002) Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading fiame, and NS2 coding regions. RNA 8: 557-571.
62. Kuiken C, Yusim K, Boykin L, Richardson R (2005) The Los Alamos hepatitis C sequence database. Bioinformatics 21: 379-384.
63. Kumar S, Tamura K, Nei M (2004) MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 5: 150-163.
64. Fares MA (2004) SWAPSC: sliding window analysis procedure to detect selective constraints. Bioinformatics 20: 2867-2868.
65. Ewing B, Green P (1998) Base-calling of automated sequencer traces using pored. II. Error probabilities. Genome Res 8: 186-194.
66. Ewing B, Hillier L, Wendl MC, Green P (1998) Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 8: 175-185.